The etiology of paraneoplastic autoimmunity

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 2, 2012, Pages 135-144

  Maverakis, Emanual ^a,b   Goodarzi, Heidi ^a   Wehrli, Lisa N ^a   Ono, Yoko ^a   Garcia, Miki Shirakawa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Veteran Affairs Northern California Health Care System ^*  (United States)

Author keywords

Autoimmunity; CLL; Myasthenia gravis; Non Hodgkin's lymphoma; Paraneoplastic pemphigus; Pemphigus vulgaris; Pyoderma gangrenosum; Self; Sweet's syndrome; Thymoma

Indexed keywords

AMPHIPHYSIN; AUTOIMMUNE REGULATOR PROTEIN; B7 ANTIGEN; BULLOUS PEMPHIGOID ANTIGEN 1; CD28 ANTIGEN; CD86 ANTIGEN; CHOLINERGIC RECEPTOR; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; ELAFIN; ENVOPLAKIN; FLUDARABINE; GAMMA INTERFERON; GELATINASE B; GEPHYRIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERIPLAKIN; PLECTIN; RECOMBINANT ERYTHROPOIETIN; RECOVERIN; STROMELYSIN 2; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; CELL SELECTION; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; ENTERITIS; GENE REARRANGEMENT; HUMAN; IMMUNE DYSREGULATION; MEDULLA OBLONGATA; MYASTHENIA GRAVIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; PARANEOPLASTIC AUTOIMMUNITY; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC SYNDROME; PYODERMA GANGRENOSUM; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; THYMOMA; UPREGULATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CELL TRANSFORMATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; PARANEOPLASTIC SYNDROMES; POLYMORPHISM, GENETIC; SKIN;

EID: 84862839721     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8248-5     Document Type: Review

References (82)

1. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T (1998) Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 102:775-782 (Pubitemid 28399610)
2. Futei Y, Amagai M, Hashimoto T, Nishikawa T (2003) Confor-mational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol 49:1023-1028 (Pubitemid 37475473)
3. Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155-157
4. Bowen GM et al (2000) Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 136:652-656 (Pubitemid 30304947)
5. Wang L, Bu D, Yang Y, Chen X, Zhu X (2004) Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 363:525-531 (Pubitemid 38229453)
6. Anhalt GJ et al (1990) Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323:1729-1735
7. Sehgal VN, Srivastava G (2009) Paraneoplastic pemphigus/para-neoplastic autoimmune multiorgan syndrome. Int J Dermatol 48:162-169
8. Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS (2010) Cutaneous manifestations of internal malignancy Curr Probl Surg 47:384-445
9. Martinez De Pablo MI et al (2005) Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol 85:233-235 (Pubitemid 40695166)
10. Mimouni D et al (2002) Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147:725-732 (Pubitemid 35286158)
11. Billet SE, Grando SA, Pittelkow MR (2006) Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 39:617-630 (Pubitemid 44768931)
12. Buck T, Gonzalez LM, Lambert WC, Schwartz RA (2008) Sweet's syndrome with hematologic disorders: a review and reappraisal. Int J Dermatol 47:775-782
13. Zappasodi P, Forno C, Corso A, Lazzarino M (2006) Mucocuta-neous paraneoplastic syndromes in hematologic malignancies. Int J Dermatol 45:14-22
14. Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations oflymphoproliferative disorders. Autoimmun Rev 9:A335-A341
15. Perry HO, Brunsting LA (1957) Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch Derm 75:380-386
16. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence ofextraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116-1122 (Pubitemid 32319146)
17. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG (2001) Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody Arch Dermatol 137:930-933 (Pubitemid 32641653)
18. Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of792 patients. J Clin Gastroenterol 23:29-34 (Pubitemid 26244497)
19. Brunsting LA, Goeckerman WH, O'Leary PA (1930) Pyoderma (echthyma) gangrenosum-clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph 22:655-680
20. Bennett ML et al (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79:37-46 (Pubitemid 30077735)
21. Duguid CM, O'Loughlin S, Otridge B, Powell FC (1993) Paraneo-plastic pyoderma gangrenosum. Australas J Dermatol 34:17-22
22. Oka M et al (2000) Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 80:595-604 (Pubitemid 30226640)
23. Oka M (2007) Pyoderma gangrenosum and interleukin 8. Br J Dermatol 157:1279-1281
24. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S (2000) Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 143:728-732
25. Saito S et al (2006) CD30+ anaplastic large cell lymphoma complicated by pyoderma gangrenosum with increased levels of serum cytokines. Eur J Haematol 77:251-254 (Pubitemid 44181389)
26. Kawakami T, Yamazaki M, Soma Y (2009) Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol 104:2363-2364
27. Bister V, Makitalo L, Jeskanen L, Saarialho-Kere U (2007) Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangreno-sum. J Cutan Pathol 34:889-898 (Pubitemid 350132001)
28. Brooklyn TN et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505-509
29. Mittal S, Milner BJ, Vickers MA (2005) Pyoderma gangrenosum as a cause of splenomegaly and association with a T-cell clone. Clin Lab Haematol 27:402-404 (Pubitemid 41784352)
30. Brooklyn TN, Williams AM, Dunnill MG, Probert CS (2007) T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 157:960-966 (Pubitemid 47583536)
31. Su WP, Schroeter AL, Perry HO, Powell FC (1986) Histopatho-logic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 13:323-330 (Pubitemid 16009117)
32. Gapin L et al (1998) Quantitative analysis of the T cell repertoire selected by a single peptide-major histocompatibility complex. J Exp Med 187:1871-1883 (Pubitemid 28262450)
33. Maverakis E et al (2003) Autoreactive T cells can be protected from tolerance induction through competition by flanking determi-nants for access to class II MHC. Proc Natl Acad Sci USA 100:5342-5347 (Pubitemid 36542707)
34. Sercarz EE, Maverakis E (2003) Mhc-guided processing: binding oflarge antigen fragments. Nat Rev Immunol 3:621-629 (Pubitemid 37328665)
35. Maverakis E, Beech JT, Schneider S, Sercarz EE (2008) Presentation of a determinant by MHC class II can be prevented through competitive capture by a flanking determinant on a multideterminant peptide. J Autoimmun 31:59-65
36. Gammon G, Sercarz E (1989) How some T cells escape tolerance induction. Nature 342:183-185 (Pubitemid 19277018)
37. Engels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546-551 (Pubitemid 36578561)
38. Melms A et al (2006) Thymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cells. Acta Neurol Scand Suppl 183:12-13
39. Wadhera A et al (2007) Thymoma-associated multiorgan autoim-munity: A graft-versus-host-like disease. J Am Acad Dermatol 57 (4):683-689 (Pubitemid 47384913)
40. Nagvekar N et al (1998) A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101:2268-2277 (Pubitemid 28244111)
41. Moschella SL (1967) Pyoderma gangrenosum. A patient success-fully treated with intralesional injections of steroid. Arch Dermatol 95:121-123
42. Jennings JL (1983) Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol 9:575-580 (Pubitemid 13007756)
43. Mrowietz U, Christophers E (1991) Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br J Dermatol 125:499
44. Rosenow EC 3rd, Hurley BT (1984) Disorders of the thymus. A review. Arch Intern Med 144:763-770 (Pubitemid 14173521)
45. Lara PN Jr (2000) Malignant thymoma: current status and future directions. Cancer Treat Rev 26:127-131
46. Good RA (1954) Agammaglobulinaemia: a provocative experi-ment ofnature. Bull Univ Minn Hosp 26:1-19
47. Fujimoto W et al (2002) Paraneoplastic pemphigus associated with Castleman's disease and asymptomatic bronchiolitis obliter-ans. Eur J Dermatol 12:355-359 (Pubitemid 34713102)
48. Wang J et al (2005) Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneo-plastic pemphigus. Br J Dermatol 153:558-564 (Pubitemid 41248213)
49. Wang J et al (2005) Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 141:1285-1293 (Pubitemid 41498927)
50. Nikolskaia OV, Nousari CH, Anhalt GJ (2003) Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 149:1143-1151 (Pubitemid 38058089)
51. Kim WY, Kim H, Jeon YK Kim CW (2010) Follicular dendritic cell sarcoma with immature T-cell proliferation. Hum Pathol 41:129-133
52. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction ofanergy in T-cell clones. Nature 356:607-609
53. Thompson ED, Enriquez HL, Fu YX, Engelhard VH (2010) Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 207:1791-1804
54. Hamblin TJ (2006) Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33:230-239
55. Dearden C (2008) Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, pp 450-456
56. Tomic J et al (2006) Sensitization ofIL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 176:3830-3839 (Pubitemid 43364032)
57. Jablonska E et al (2005) TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 46:1307-1312 (Pubitemid 41269297)
58. Hall AM, Vickers MA, McLeod E, Barker RN (2005) Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105:2007-2015 (Pubitemid 40731785)
59. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 Tcells. J Clin Invest 115:1797-1805 (Pubitemid 40979718)
60. Ramsay AG et al(2008) Chronic lymphocytic leukemiaTcells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437 (Pubitemid 351949771)
61. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433-441
62. Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511-6521
63. Beyer M et al (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018-2025 (Pubitemid 41291715)
64. Dearden C et al (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence ofhemolytic anemia. Blood 111:1820-1826 (Pubitemid 351451488)
65. Citores MJ et al (2010) CD154 expression triggered by purine analogues in vitro: correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. Exp Hematol 38:165-173
66. Gooptu C et al (2001) Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 144:1255-1261 (Pubitemid 34204223)
67. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
68. Di Bernardo MC et al (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40:1204-1210
69. Shaffer AL et al (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231 (Pubitemid 351969894)
70. Biswas PS et al (2010) Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 120:3280-3295
71. Novak AJ et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69:4217-4224
72. Juszczynski P et al (2002) Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 100:3037-3040
73. Chu VT et al (2009) Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083-2093
74. Zhang W et al (2010) B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad SciUSA 107:18956-18960
75. Lang B, Vincent A (1996) Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 8:865-871 (Pubitemid 27007654)
76. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y (2001) The dual association between lymphoma and autoimmunity. Blood Cell Mol Diseases 27:750-756 (Pubitemid 33022303)
77. Dalmau J et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25-36 (Pubitemid 46214241)
78. Butler MH et al (2000) Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26:307-312
79. Polans AS et al (1995) Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 92:9176-9180
80. Buckanovich RJ, Yang YYL, Darnell RB (1996) The onconeural antigen Nova-1 is a neuron-specific RNA-Binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 16:1114-1122 (Pubitemid 26140868)
81. Lennon VA et al (1995) Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467-1474
82. Yu Z et al (2001) CRMP-5 neuronal autoantibody: marker oflung cancer and thymoma-related autoimmunity. Ann Neurol 49:146-154 (Pubitemid 32157990)